Protocol Design, Compliance, and Feasibility of Frequent Remote Monitoring in Patients Receiving Lecanemab

Abstract

Background: Anti‐amyloid disease‐modifying therapies (DMTs) for Alzheimer's Disease (AD) such as lecanemab are being increasingly prescribed. This mandates more frequent and in‐depth tracking of patients receiving these agents in order to better estimate their cognitive, behavioral, and functional trajectories while receiving treatment.

The paper